National Institute of Mental Health; Notice of Closed Meeting, 36564 [2021-14737]

Download as PDF 36564 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices Country Title Application No. United States ......... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–US–16 ...................................... United States ......... Australia ................. Brazil ...................... Canada .................. China ...................... Colombia ................ Eurasia ................... Europe ................... Hong Kong ............. Oligonucleotide Analogues Targeting Human LMNA .................................................................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–AU–03 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–BR–04 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CA–05 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CN–06 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CO–07 ..................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–EA–08 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–EP–09 ...................................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–HK–17. Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–IN–10 ....................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–JP–11 ....................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–KR–12 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–MX–13 ..................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–NZ–14 ...................................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–SG–15 ...................................... 16/096,524 (371national phase). 17/024,100. 2017258642. BR1120180722790. 3,022,303. 201780040785.7. NC2018/0012783. 201892467. 17735676.3. 19126894.5. khammond on DSKJM1Z7X2PROD with NOTICES India ....................... Japan ..................... Korea (South) ........ Mexico .................... New Zealand .......... Singapore ............... The patent rights in these inventions have been assigned to the Government of the United States of America, the University of Maryland, Sarepta Therapeutics, Inc, and the Progeria Research Foundation (PRF), co-owners of said rights, for commercial development and marketing. The rights to be granted by NHGRI are controlled by NHGRI by virtue of co-ownership and a license received to the listed intellectual property. The prospective patent license will be for the purpose of consolidating the patent rights to PRF. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212. The prospective patent license will be worldwide, exclusive, may be limited to those fields of use commensurate in scope with the patent rights, and will be sublicensable. The subject technology pertains to modified oligonucleotides (called phosphorodiamidate morpholino oligonucleotides or PMOs) targeted to pre-mRNA of human LMNA Lamin A gene. These PMOs can be used to correct aberrant splicing of LMNA gene known to be involved in HutchinsonGilford Progeria Syndrome (HGPS), and could be used in treating this ultra-rare disease and related laminopathies. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective Exclusive Patent License will be royalty bearing and may be granted unless, within fifteen (15) days from the date of this published notice, the NHGRI Technology Transfer Office receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license that are timely filed in response to this notice will be treated as objections to VerDate Sep<11>2014 17:26 Jul 09, 2021 Jkt 253001 this to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. Dated: June 29, 2021. Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute, National Institutes of Health. [FR Doc. 2021–14702 Filed 7–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Mental Health Council. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 Patent No. 10,822,608 201847043433. 2019–508165. 10–2018–7034615. MX/A/2018/013157. 747685. 11201809468X. applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Mental Health Council. Date: August 6, 2021. Time: 3:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Tracy Lynn Waldeck, Ph.D., Director, Division of Extramural Activities, National Institute of Mental Health, Neuroscience Center, 6001 Executive Boulevard, Room 4133, Rockville, MD 20892, (301) 480–6833, waldeckt@mail.nih.gov. Information is also available on the Institute’s/Center’s home page: www.nimh.nih.gov/about/advisory-boardsand-groups/namhc/index.shtml, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: July 7, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–14737 Filed 7–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council. The meeting will be closed to the public in accordance with the E:\FR\FM\12JYN1.SGM 12JYN1

Agencies

[Federal Register Volume 86, Number 130 (Monday, July 12, 2021)]
[Notices]
[Page 36564]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14737]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Mental Health; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Mental Health Council.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Advisory Mental Health Council.
    Date: August 6, 2021.
    Time: 3:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications and/or 
proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Tracy Lynn Waldeck, Ph.D., Director, Division of 
Extramural Activities, National Institute of Mental Health, 
Neuroscience Center, 6001 Executive Boulevard, Room 4133, Rockville, 
MD 20892, (301) 480-6833, [email protected].

    Information is also available on the Institute's/Center's home 
page: www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/index.shtml, where an agenda and any additional information for the 
meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental 
Health Research Grants, National Institutes of Health, HHS)

    Dated: July 7, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-14737 Filed 7-9-21; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.